I have come across some promising, but early, research into a drug known as DpC that is claimed to inhibit prostate-specific antigen (PSA) as well as suppressing both androgen-dependent and independent arms of androgen receptor signaling.
Developed by Griffith University researcher Professor Des Richardson and colleagues from the University of Sydney., this new anti-cancer drug for prostate cancer that overcomes the twin problems plaguing researchers for decades. It halts metastasis (tumor spread) and drug resistance.
“This drug is the first to exhibit such potent androgen receptor suppression, critical for overcoming the development of androgen resistance, a major killer in prostate cancer.”
Title: The metastasis suppressor, NDRG1: A signaling guru in inhibiting
cancer migration and growth
Presenter: Professor Des Richardson, Chair of Cancer Cell Biology NHMRC Senior Principal Research Fellow. The University of Sydney
When: Monday 16 July, 2018 @ 1pm
Venue: Room 1.81, Anatomy, Physiology & Human Biology Building North
The University of Western Australia (off Hackett Entrance No. 2)
Speaker: Professor Des Richardson holds the Chair of Cancer Cell Biology at the University of Sydney, Australia, and is a National Health and Medical Research Council (NHMRC) of Australia Senior Principal Research Fellow.
He has published > 407 articles, reviews, patents, chapters etc., over his career
As a major translational research achievement, he has developed the anticancer and anti-metastatic drug, DpC, which overcomes P-glycoprotein mediated drug resistance. This has led to commercialisation of DpC and the development of the international company, Oncochel Therapeutics LLC, USA and its Australian subsidiary, Oncochel Therapeutics Pty Ltd. Notably, DpC has entered multicentre Phase I clinical trials for the treatment of advanced and resistant cancer.
Abstract: The iron-regulated metastasis suppressor N-myc downstream-regulated gene 1 (NDRG1) has been shown to inhibit numerous oncogenic signaling pathways in cancer cells. Recent findings have demonstrated that NDRG1 inhibits the ErbB family of receptors, which function as key inducers of carcinogenesis. NDRG1 attenuates ErbB signaling by inhibiting formation of epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) and HER2/HER3 heterodimers and by down-regulating EGFR via a mechanism involving its degradation.
Understanding the complex interplay between NDRG1, iron, and ErbB signaling is vital for identifying novel, more effective targets for cancer therapy.
I hope that this clinical trial will be available in the US.
May be we need to contact Oncochel Therapeutics, since thye are operating in the US?
When do you think that this therapy could become commercially available if it makes it through the trials to FDA approval? I deeply appreciate the contribution of researchers like this, but WTH was he thinking with that Wayne Newton hair?
I did wonder if the hair would undermine his credibility. But I am envious of anyone with a full head of hair. I was skeptical about the lack of grey. LOL.
The FDA can fast-track products these days. In the old days it might take 10+ years.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Can melatonin control AR amplification and therefore help mCRPC drugs work better and longer? 
'Substandard' Control Arms in Clinical Trials– Practice found common in prostate cancer studies
